Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.

[1]  G. Daley,et al.  Chronic Myeloid Leukemia : Biology and Treatment , 2003 .

[2]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[3]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[4]  M. Baccarani,et al.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. , 2001, Blood.

[5]  M. Pfirrmann,et al.  Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α‐interferon: comments , 2001, British journal of haematology.

[6]  J. Irving,et al.  Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia , 2001, Journal of clinical pathology.

[7]  B. Druker,et al.  Chronic myelogenous leukemia , 2001, Current opinion in oncology.

[8]  M. Baccarani,et al.  Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. , 2000, British journal of haematology.

[9]  M. Baccarani,et al.  Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α‐interferon , 2000 .

[10]  P. Cony-Makhoul,et al.  Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. , 1998, Blood.

[11]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[12]  J. Hasford,et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.

[13]  I. Weissman,et al.  Systemic Overexpression of BCL-2 in the Hematopoietic System Protects Transgenic Mice From the Consequences of Lethal Irradiation , 1998 .

[14]  C Chastang,et al.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.

[15]  W. Hilbe,et al.  Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group. , 1996, Bone marrow transplantation.

[16]  N. Schmitz,et al.  Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. , 1996, Bone marrow transplantation.

[17]  Joerg Hasford,et al.  Analysis and validation of prognostic factors for CML , 1996 .

[18]  R Ohno,et al.  A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. , 1995, Blood.

[19]  H. Heimpel,et al.  Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. , 1994, Blood.

[20]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[21]  Sante Tura,et al.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.

[22]  C. Bloomfield,et al.  Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583 , 1993 .

[23]  D. Niederwieser,et al.  Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. , 1993, Seminars in hematology.

[24]  H. Kantarjian,et al.  Clinical investigation of human alpha interferon in chronic myelogenous leukemia. , 1987, Blood.

[25]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[26]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[27]  R. Isaacs,et al.  CHRONIC MYELOGENOUS LEUKEMIA: AGE INCIDENCE, DURATION, AND BENEFIT DERIVED FROM IRRADIATION , 1924 .